Pfizer's Options Frenzy: What You Need to Know

Deep-pocketed investors have adopted a bullish approach towards Pfizer PFE, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in PFE usually suggests something big is about to happen.

We gleaned this information from our observations today when Benzinga's options scanner highlighted 28 extraordinary options activities for Pfizer. This level of activity is out of the ordinary.

The general mood among these heavyweight investors is divided, with 46% leaning bullish and 46% bearish. Among these notable options, 8 are puts, totaling $983,126, and 20 are calls, amounting to $1,108,869.

Expected Price Movements

Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $20.0 to $35.0 for Pfizer during the past quarter.

Analyzing Volume & Open Interest

Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.

This data can help you track the liquidity and interest for Pfizer's options for a given strike price.

Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Pfizer's whale activity within a strike price range from $20.0 to $35.0 in the last 30 days.

Pfizer Call and Put Volume: 30-Day Overview

Noteworthy Options Activity:

About Pfizer

Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.

After a thorough review of the options trading surrounding Pfizer, we move to examine the company in more detail. This includes an assessment of its current market status and performance.

Current Position of Pfizer

• Currently trading with a volume of 52,196,111, the PFE's price is up by 1.47%, now at $28.22.
• RSI readings suggest the stock is currently may be approaching overbought.
• Anticipated earnings release is in 85 days.

Professional Analyst Ratings for Pfizer

A total of 4 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $38.75.

• Reflecting concerns, an analyst from Cantor Fitzgerald lowers its rating to Overweight with a new price target of $45.
• In a cautious move, an analyst from Cantor Fitzgerald downgraded its rating to Overweight, setting a price target of $45.
• Reflecting concerns, an analyst from BMO Capital lowers its rating to Outperform with a new price target of $36.
• An analyst from Morgan Stanley has decided to maintain their Equal-Weight rating on Pfizer, which currently sits at a price target of $29.

Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Pfizer with Benzinga Pro for real-time alerts.